Abstract
Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. Potential ancillary benefits of duquetide therapy were also identified.
Document Type
Article
Publication Date
9-2017
Digital Object Identifier (DOI)
https://doi.org/10.1016/j.btre.2017.05.002
Funding Information
A portion of this work was supported by the National Institute of Dental and Craniofacial Research Small Business Innovation Research grant # 1R43 DE024032-01(Soligenix, Inc).
Repository Citation
Kudrimoti, Mahesh; Curtis, Amarinthia; Azawi, Samar; Worden, Francis; Katz, Sanford; Adkins, Douglas; Bonomi, Marcelo; Scott, Zack; Elder, Jenna; Sonis, Stephen T.; Straube, Richard; and Donini, Oreola, "Dusquetide: Reduction in Oral Mucositis Associated with Enduring Ancillary Benefits in Tumor Resolution and Decreased Mortality in Head and Neck Cancer Patients" (2017). Radiation Medicine Faculty Publications. 19.
https://uknowledge.uky.edu/radmed_facpub/19
Notes/Citation Information
Published in Biotechnology Reports, v. 15, p. 24-26.
© 2017 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).